ContraVir Pharmaceuticals anounces pricing of $2.14 million public offering
ContraVir Pharma announced the pricing of a public offering with expected total gross proceeds of $2,140,000. Roth Capital Partners is acting as the lead placement agent for the offering. Brookline Capital Markets, a Division of CIM Securities is acting as co-placement agent for the offering. April 25, 2019